LPOXY Therapeutics is developing a convenient, orally administered capsule to deliver oxygen directly to the bowel to treat inflammatory bowel diseases (IBD). Clinical studies have demonstrated that patients breathing oxygen significantly increase their colon oxygen and hyperbaric oxygen's effectiveness in the treatment of Crohn's disease (CD) and ulcerative colitis (UC). We’re simplifying and revolutionizing the process with enteric aerobization, transporting oxygen directly to the bowel via an oral capsule. Clostridioides difficile infections (CDI) commonly occur in acutely ill Ulcerative colitis (UC) patients and are associated with increased risks of colectomy and mortality. However, the most common cause of CDI is colonic microbiome disruption caused by antibiotic therapy. CDI causes 500,000 infections and 30,000 deaths annually in the USA and is considered by the CDC an urgent threat pathogen. LPOXY is working to prevent CDI in both UC patients and patients being treated with systemic antibiotics by using OXYGEN. Intestinal oxygen is well tolerated in animals and humans. LPOXY has assembled an industry-leading drug development and regulatory affairs team.
